Advancing small molecules with immune effects.
At the leading edge of oncology.
Solving problems that haven’t been solved.
Addressing needs that haven’t been met.
We are developing novel small molecules with immunotherapeutic effects. Our lead agent, PT-112, has been shown in Phase 2 patients to generate adaptive and innate anti-cancer immune responses.
PT-112 has reached the End of Phase 2 (EOP2) milestone.
Promontory Therapeutics was a Prix Galien USA Best Startup Nominee in 2023
Learn about our lead clinical drug candidate.
How our agent induces an adaptive immune response.
Why Promontory is different from others.
News and updates.
Have questions?
Reach out to us to learn more about our company, science, potential partnerships or other opportunities.